Table 2. Demographics, comorbidity and transplant characteristics of transplant recipients stratified by vaccine response.
| Table 2: Characteristics according to seroconversion status | |||
|---|---|---|---|
| Total Cohort (n = 373) | Seropositive Response(n = 212) | Seronegative Response(n = 161) | |
| Antibody status post vaccine | 373 | 212(56.8) | 161(43.2) |
| Age (Years) | 55±14 | 51±14 | 58±13 |
| Male | 228(60) | 136(64) | 92(57) |
| Caucasian | 312(83.6) | 174(82.1) | 138(85.7) |
| BAME | 60(16.1) | 38(17.9) | 22(13.7) |
| Months from transplantation | 91(48–156) | 110(59–156) | 71.5(30–122) |
| Live donor | 135(37) | 77(36.8) | 58(37.2) |
| Comorbidities | |||
| BMI | 27.3(5.8) | 27.7± 6.1 | 26.9 ± 5.3 |
| Diabetes | 123(33) | 66(31.1) | 57(35.4) |
| CVD | 92(24.7) | 43(20.3) | 49(30.4) |
| Post-transplant cancerα | 24(6.4) | 12(5.7) | 12(7.5) |
| Immunosuppression | |||
| CNI | 350(93.8) | 194(91.5) | 156(96.9) |
| MPA | 263(70.5) | 115(54.3) | 148(91.9) |
| Azathioprine | 46(12.3) | 41(19.3) | 5(3.1) |
| Corticosteroid | 134(36) | 85(40.1) | 49(30.4) |
| Triple IS | 83(22.3) | 45(21.2) | 38(23.6) |
| Dual IS | 261(70) | 139(65.6) | 122(75.8) |
| Single IS | 29(7.8) | 28(13.2) | 1(0.62) |
| eGFR [(MDRD) (ml/min/1.73m2] | 47(34–60) | 49(36–63) | 43(33–56) |
| History Viral infection | |||
| BK viremia | 38(11.2) | 28(15) | 10(6.28) |
| CMV infection | 41(12.0) | 19(10.2) | 22(14.3) |
| EBV infection | 26(7.7) | 12(6.4) | 14(9.2) |
| JCV | 9(2.7) | 4(2.1) | 5(3.3) |
| Prior Acute rejection | 60(16.1) | 44(20.8) | 16(9.9) |
| Vaccine type | |||
| AZD1222 | 84(28) | 50(30.5) | 34(25.0) |
| BNT162b2 | 216(72) | 114(69.5) | 102(75) |
| Days from vaccine to antibody test | 38(22–55) | 38(19–54) | 39(24–55) |
| Post Vaccination COVID-19 infection | 10(2.6) | 2(1) | 8(5) |
AZD1222, Oxford/AstraZeneca vaccine; BNT162b2, Pfizer-BioNTech vaccine; BAME, Black Asian and minority ethnic group; BMI, body mass index; Categorical variables are presented as numbers (percentages), continuous variables were presented as mean± standard deviation or median (inter-quartile range); CMV, cytomegalovirus; CNI, calcineurin inhibitor; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; EBV, Epstein bar virus; IS, immunosuppression; MPA, mycophenolic acid; MDRD, modification of diet in Renal disease;.α, excluding non-melanoma skin cancer